When did Madrigal Pharmaceuticals, Inc. report Q4 2024 earnings?

Madrigal Pharmaceuticals, Inc. (MDGL) reported Q4 2024 earnings on February 26, 2025 before market open.

What were Madrigal Pharmaceuticals, Inc.'s Q4 2024 revenue and EPS?

Madrigal Pharmaceuticals, Inc. reported revenue of $103.3M and eps of $-2.71 for Q4 2024.

Did Madrigal Pharmaceuticals, Inc. beat estimates in Q4 2024?

Revenue beat the consensus estimate of $97.8M by $5.5M. EPS beat the consensus estimate of $-4.32 by $1.61.

Where can I find Madrigal Pharmaceuticals, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0001628280-25-007980) directly on SEC EDGAR. The filing index links above go to sec.gov.

Madrigal Pharmaceuticals, Inc. MDGL Q4 2024 Annual earnings

Reported February 26, 2025 · Before market open

Revenue$103.3MBeat by $5.5M

EPS-$2.71Beat by $1.61

Revenue estimate$97.8M

EPS estimate-$4.32

Next report

Jul 30, 2026 (Tomorrow)

Revenue estimate$351.4M

EPS estimate-$2.66

Financials

Q4 2024

Income statement

See full

Revenue$103.3M—

Gross profit$43.5M—

Operating income-$67.0M+42.8%

Net income-$59.4M+47.0%

Balance sheet

See full

Cash & equivalents$105.0M+5.1%

Total debt$119.6M+2.0%

Total equity$754.4M+86.1%

Total assets$1.0B+62.7%

Cash flow

See full

Operating cash flow-$104.5M-30.7%

CapEx$195.0K-81.2%

Free cash flow-$104.7M-29.3%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$6.73B+47.3%

Enterprise value$6.74B+47.1%

P/S37.4×—

Profitability

See full

Gross margin96.5%—

Operating margin-276.4%—

Net margin-258.6%—

FCF margin-253.7%—

Returns & leverage

See full

Return on equity-80.3%-20.9pp

Debt / equity0.2×-0.1×

Current ratio6.1×+0.7×

Segments

By segment

See full

Reportable Segment$103.3M—

Versus estimates

Revenue

Q1 2026$311.3MBeat by $10.3M Q4 2025$321.1MBeat by $8.6M Q3 2025$287.3MBeat by $42.3M Q2 2025$212.8MMiss by $30.7M Q1 2025$137.3MMiss by $21.7M

Q4 2024$103.3MBeat by $5.5M

Diluted EPS

Q1 2026-$3.25Beat by $0.36 Q4 2025-$2.57Miss by $2.61 Q3 2025-$5.08Miss by $3.04 Q2 2025-$1.90Beat by $1.58 Q1 2025-$3.32Beat by $0.30

Q4 2024-$2.71Beat by $1.61

Ask the moment Madrigal Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Madrigal Pharmaceuticals, Inc. report Q4 2024 earnings?: Madrigal Pharmaceuticals, Inc. (MDGL) reported Q4 2024 earnings on February 26, 2025 before market open.
What were Madrigal Pharmaceuticals, Inc.'s Q4 2024 revenue and EPS?: Madrigal Pharmaceuticals, Inc. reported revenue of $103.3M and eps of $-2.71 for Q4 2024.
Did Madrigal Pharmaceuticals, Inc. beat estimates in Q4 2024?: Revenue beat the consensus estimate of $97.8M by $5.5M. EPS beat the consensus estimate of $-4.32 by $1.61.
Where can I find Madrigal Pharmaceuticals, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001628280-25-007980) directly on SEC EDGAR. The filing index links above go to sec.gov.